Skip to main navigation Skip to search Skip to main content

Plasma HDL cholesterol and risk of myocardial infarction: A mendelian randomisation study

  • Benjamin F. Voight
  • , Gina M. Peloso
  • , Marju Orho-Melander
  • , Ruth Frikke-Schmidt
  • , Maja Barbalic
  • , Majken K. Jensen
  • , George Hindy
  • , Hilma Hólm
  • , Eric L. Ding
  • , Toby Johnson
  • , Heribert Schunkert
  • , Nilesh J. Samani
  • , Robert Clarke
  • , Jemma C. Hopewell
  • , John F. Thompson
  • , Mingyao Li
  • , Gudmar Thorleifsson
  • , Christopher Newton-Cheh
  • , Kiran Musunuru
  • , James P. Pirruccello
  • Danish Saleheen, Li Chen, Alexandre F.R. Stewart, Arne Schillert, Unnur Thorsteinsdottir, Gudmundur Thorgeirsson, Sonia Anand, James C. Engert, Thomas Morgan, John Spertus, Monika Stoll, Klaus Berger, Nicola Martinelli, Domenico Girelli, Pascal P. McKeown, Christopher C. Patterson, Stephen E. Epstein, Joseph Devaney, Mary Susan Burnett, Vincent Mooser, Samuli Ripatti, Ida Surakka, Markku S. Nieminen, Juha Sinisalo, Marja Liisa Lokki, Markus Perola, Aki Havulinna, Ulf De Faire, Bruna Gigante, Erik Ingelsson, Tanja Zeller, Philipp Wild, Paul I.W. De Bakker, Olaf H. Klungel, Anke Hilse Maitland-Van Der Zee, Bas J.M. Peters, Anthonius De Boer, Diederick E. Grobbee, Pieter W. Kamphuisen, Vera H.M. Deneer, Clara C. Elbers, N. Charlotte Onland-Moret, Marten H. Hofker, Cisca Wijmenga, W. M.Monique Verschuren, Jolanda M.A. Boer, Yvonne T. Van Der Schouw, Asif Rasheed, Philippe Frossard, Serkalem Demissie, Cristen Willer, Ron Do, Jose M. Ordovas, Gonçalo R. Abecasis, Michael Boehnke, Karen L. Mohlke, Mark J. Daly, Candace Guiducci, Noël P. Burtt, Aarti Surti, Elena Gonzalez, Shaun Purcell, Stacey Gabriel, Jaume Marrugat, John Peden, Jeanette Erdmann, Patrick Diemert, Christina Willenborg, Inke R. König, Marcus Fischer, Christian Hengstenberg, Andreas Ziegler, Ian Buysschaert, Diether Lambrechts, Frans Van De Werf, Keith A. Fox, Nour Eddine El Mokhtari, Diana Rubin, Jürgen Schrezenmeir, Stefan Schreiber, Arne Schäfer, John Danesh, Stefan Blankenberg, Robert Roberts, Ruth McPherson, Hugh Watkins, Alistair S. Hall, Kim Overvad, Eric Rimm, Eric Boerwinkle, Anne Tybjaerg-Hansen, L. Adrienne Cupples, Muredach P. Reilly, Olle Melander, Pier M. Mannucci, Diego Ardissino, David Siscovick, Roberto Elosua, Kari Stefansson, Christopher J. O'Donnell, Veikko Salomaa, Daniel J. Rader, Leena Peltonen, Stephen M. Schwartz, David Altshuler, Sekar Kathiresan*
*Corresponding author for this work
  • University of Pennsylvania
  • Harvard University
  • Broad Institute
  • University of Michigan
  • Boston University School of Medicine
  • NHLBI's Framingham Heart Study
  • Diabetes and Cardiovascular Disease Genetic Epidemiology
  • Skåne University Hospital Malmö
  • Department of Clinical Biochemistry
  • University of Copenhagen, Denmark
  • Human Genetics Center
  • Baylor College of Medicine
  • University of Iceland
  • Department of Nutrition
  • Clinical Pharmacology and the Genome Centre
  • Queen Mary University of London
  • Department of Health Sciences
  • Leicester National Institute for Health Research Biomedical Research Unit in Cardiovascular Disease
  • Glenfield Hospital
  • Department of Cardiovascular Medicine
  • Biostatistics and Epidemiology
  • Cardiovascular Research Center
  • Cardiovascular Research Center and Cardiology Division
  • Department of Public Health and Primary Care
  • University of Cambridge
  • John and Jennifer Ruddy Canadian Cardiovascular Genetics Centre
  • University of Ottawa
  • Hamilton Health Sciences
  • McGill University
  • Department of Pediatrics
  • Vanderbilt University
  • University of Missouri-Kansas City
  • Leibniz-Institute for Arteriosclerosis Research
  • University of Münster
  • University of Verona
  • Institute of Clinical Science
  • Cardiovascular Research Foundation
  • MedStar Washington Hospital Center
  • Genetics Division and Drug Discovery
  • GlaxoSmithKline
  • University of Helsinki
  • National Public Health Institute
  • Division of Cardiovascular Epidemiology
  • Karolinska Institutet
  • Department of Medical Epidemiology and Biostatistics
  • Johannes Gutenberg University Mainz
  • Utrecht University
  • Division of Pharmaco Epidemiology and Clinical Pharmacology
  • University of Groningen
  • Department of Clinical Pharmacy
  • St. Antonius Ziekenhuis
  • Center for Prevention and Health Services Research
  • National Institute for Public Health and the Environment
  • Center for Nutrition and Health
  • Center for Non-Communicable Diseases
  • Tufts University
  • Department of Cardiovascular Epidemiology and Population Genetics
  • Centro Nacional de Investigaciones Cardiovasculares Carlos III
  • University of North Carolina
  • Cardiovascular Epidemiology and Genetics
  • Cardiovascular Epidemiology and Genetics Group
  • University of Regensburg
  • KU Leuven
  • Institute of Epidemiology and Social Medicine
  • Cardiovascular Research
  • University of Edinburgh
  • University of Kiel
  • LIGHT and LIMM Research Institutes
  • University of Leeds
  • Aarhus University
  • Copenhagen University Hospital Bispebjerg
  • Institute of Translational Medicine and Therapeutics
  • Lund University
  • Department of Internal Medicine and Medical Specialities
  • IRCCS Fondazione Don Carlo Gnocchi - Milano
  • University of Parma
  • University of Washington, Seattle
  • CIBER Epidemiologia y Salud Pública (CIBERESP)
  • Wellcome Sanger Institute

Abstract

Background High plasma HDL cholesterol is associated with reduced risk of myocardial infarction, but whether this association is causal is unclear. Exploiting the fact that genotypes are randomly assigned at meiosis, are independent of non-genetic confounding, and are unmodified by disease processes, mendelian random isation can be used to test the hypothesis that the association of a plasma biomarker with disease is causal. Methods We performed two mendelian randomisation analyses. First, we used as an instrument a single nucleotide polymorphism (SNP) in the endothelial lipase gene (LIPG Asn396Ser) and tested this SNP in 20 studies (20 913 myocardial infarction cases, 95 407 controls). Second, we used as an instrument a genetic score consisting of 14 common SNPs that exclusively associate with HDL cholesterol and tested this score in up to 12 482 cases of myocardial infarction and 41 331 controls. As a positive control, we also tested a genetic score of 13 common SNPs exclusively associated with LDL cholesterol. Findings Carriers of the LIPG 396Ser allele (2·6% frequency) had higher HDL cholesterol (0·14 mmol/L higher p=8×10-13) but similar levels of other lipid and non-lipid risk factors for myocardial infarction compared with noncarriers. This difference in HDL cholesterol is expected to decrease risk of myocardial infarction by 13% (odds ratio [OR] 0·87, 95% CI 0·84-0·91). However, we noted that the 396Ser allele was not associated with risk of myocardial infarction (OR 0·99, 95% CI 0·88-1·11, p=0·85). From observational epidemiology, an increase of 1 SD in HDL cholesterol was associated with reduced risk of myocardial infarction (OR 0·62, 95% CI 0·58-0·66). However, a 1 SD increase in HDL cholesterol due to genetic score was not associated with risk of myocardial infarction (OR 0·93 95% CI 0·68-1·26, p=0·63). For LDL cholesterol, the estimate from observational epidemiology (a 1 SD increase in LDL cholesterol associated with OR 1·54, 95% CI 1·45-1·63) was concordant with that from genetic score (OR 2·13 95% CI 1·69-2·69, p=2×10 -10). Interpretation Some genetic mechanisms that raise plasma HDL cholesterol do not seem to lower risk of myocardial infarction. These data challenge the concept that raising of plasma HDL cholesterol will uniformly translate into reductions in risk of myocardial infarction.

Original languageEnglish
JournalThe Lancet
Volume380
Issue number9841
Pages (from-to)572-580
Number of pages9
ISSN0140-6736
DOIs
Publication statusPublished - 01.01.2012

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being
  2. SDG 5 - Gender Equality
    SDG 5 Gender Equality

Fingerprint

Dive into the research topics of 'Plasma HDL cholesterol and risk of myocardial infarction: A mendelian randomisation study'. Together they form a unique fingerprint.

Cite this